FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM
On April 5, 2022, the Food and Drug Administration (FDA) approved alpelisib (Vijoice, Novartis Pharmaceuticals) treatment for adult and pediatric patients aged two years and older with severe manifestations of the spectrum of PIK3CA-related overgrowth syndromes (PROS) requiring systemic treatment. Efficacy was evaluated using a clinical trial of 37 patients over two years of age […]
FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM Read More »
